AU2022216216A1 - Methods of making trans isomeric forms of G protein-coupled receptor modulators - Google Patents
Methods of making trans isomeric forms of G protein-coupled receptor modulators Download PDFInfo
- Publication number
- AU2022216216A1 AU2022216216A1 AU2022216216A AU2022216216A AU2022216216A1 AU 2022216216 A1 AU2022216216 A1 AU 2022216216A1 AU 2022216216 A AU2022216216 A AU 2022216216A AU 2022216216 A AU2022216216 A AU 2022216216A AU 2022216216 A1 AU2022216216 A1 AU 2022216216A1
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- unsubstituted
- substituent group
- membered
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163144878P | 2021-02-02 | 2021-02-02 | |
| US63/144,878 | 2021-02-02 | ||
| PCT/US2022/014450 WO2022169696A1 (en) | 2021-02-02 | 2022-01-28 | Methods of making trans isomeric forms of g protein-coupled receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2022216216A1 true AU2022216216A1 (en) | 2023-08-03 |
| AU2022216216A9 AU2022216216A9 (en) | 2024-05-23 |
Family
ID=80446466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022216216A Pending AU2022216216A1 (en) | 2021-02-02 | 2022-01-28 | Methods of making trans isomeric forms of G protein-coupled receptor modulators |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12428393B2 (https=) |
| EP (1) | EP4288425A1 (https=) |
| JP (1) | JP2024505561A (https=) |
| KR (1) | KR20230152027A (https=) |
| CN (1) | CN116940564A (https=) |
| AU (1) | AU2022216216A1 (https=) |
| BR (1) | BR112023015472A2 (https=) |
| CA (1) | CA3209122A1 (https=) |
| IL (1) | IL304519A (https=) |
| MX (1) | MX2023009053A (https=) |
| TW (1) | TW202246236A (https=) |
| WO (1) | WO2022169696A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5772680A (en) | 1992-06-02 | 1998-06-30 | General Surgical Innovations, Inc. | Apparatus and method for developing an anatomic space for laparoscopic procedures with laparoscopic visualization |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10246462B2 (en) * | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| DK3743418T3 (da) * | 2018-01-26 | 2024-09-09 | Rapt Therapeutics Inc | Chemokinreceptormodulatorer og anvendelser deraf |
-
2022
- 2022-01-28 BR BR112023015472A patent/BR112023015472A2/pt unknown
- 2022-01-28 AU AU2022216216A patent/AU2022216216A1/en active Pending
- 2022-01-28 US US17/588,173 patent/US12428393B2/en active Active
- 2022-01-28 EP EP22704241.3A patent/EP4288425A1/en active Pending
- 2022-01-28 WO PCT/US2022/014450 patent/WO2022169696A1/en not_active Ceased
- 2022-01-28 KR KR1020237029665A patent/KR20230152027A/ko active Pending
- 2022-01-28 CN CN202280017473.5A patent/CN116940564A/zh active Pending
- 2022-01-28 JP JP2023546438A patent/JP2024505561A/ja active Pending
- 2022-01-28 CA CA3209122A patent/CA3209122A1/en active Pending
- 2022-01-28 MX MX2023009053A patent/MX2023009053A/es unknown
- 2022-02-07 TW TW111104352A patent/TW202246236A/zh unknown
-
2023
- 2023-07-17 IL IL304519A patent/IL304519A/en unknown
-
2025
- 2025-09-05 US US19/320,950 patent/US20260092049A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202246236A (zh) | 2022-12-01 |
| WO2022169696A8 (en) | 2023-08-31 |
| IL304519A (en) | 2023-09-01 |
| US12428393B2 (en) | 2025-09-30 |
| CN116940564A (zh) | 2023-10-24 |
| JP2024505561A (ja) | 2024-02-06 |
| US20260092049A1 (en) | 2026-04-02 |
| CA3209122A1 (en) | 2022-08-11 |
| MX2023009053A (es) | 2023-10-16 |
| WO2022169696A1 (en) | 2022-08-11 |
| US20220251070A1 (en) | 2022-08-11 |
| KR20230152027A (ko) | 2023-11-02 |
| BR112023015472A2 (pt) | 2023-11-07 |
| EP4288425A1 (en) | 2023-12-13 |
| AU2022216216A9 (en) | 2024-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3572412B1 (en) | Pyridine derivative as ask1 inhibitor and preparation method and use thereof | |
| JP6742323B2 (ja) | Ｊａｋ阻害剤 | |
| CA3062499C (en) | Benzo[f]pyrido[1,2-d][1,4]oxazepine derivatives and pharmaceutical compositions thereof useful as hepatitis b virus surface antigen inhibitor | |
| KR20190117799A (ko) | B형 간염 바이러스의 표면항원 억제제 | |
| JP2008508353A (ja) | ヒスタミンｈ３受容体リガンドとしてのピペリジン誘導体 | |
| CA2982493A1 (en) | Jak inhibitors | |
| KR102549606B1 (ko) | Hdac6 선택적 억제제 및 이의 제조방법과 응용 | |
| US20260092049A1 (en) | Methods of making trans isomeric forms of g protein-coupled receptor modulators | |
| JPS5826877A (ja) | チアゾリジニルアルキレンピペラジン誘導体 | |
| CA2576109A1 (en) | Novel piperidine derivatives as histamine h3 receptor ligands for treatment of depression | |
| EP3668852A1 (en) | Mu opioid receptor modulators | |
| Kaieda et al. | Structure-based design, synthesis, and biological evaluation of imidazo [1, 2-b] pyridazine-based p38 MAP kinase inhibitors | |
| JP2023505850A (ja) | サイクリン依存性キナーゼ９阻害剤としての化合物及びその用途 | |
| PH12014502743B1 (en) | Carbamate/urea derivatives | |
| KR102547709B1 (ko) | 아제티딘 유도체 | |
| CA3196645A1 (en) | Deuterated aminothiazole compounds as antiviral compounds | |
| CN117500796B (zh) | 亚磺酰亚胺类化合物及其应用 | |
| EP3255044B1 (en) | Diaza-benzofluoranthrene compounds | |
| US9938272B2 (en) | Hydrazine compound as blood coagulation factor Xa inhibitor | |
| EP4532483A1 (en) | Cd38 modulators and uses thereof | |
| JPS5936674A (ja) | Ｎ−置換グアニジノチアゾ−ル誘導体およびその製造法 | |
| RU2772274C2 (ru) | Селективные ингибиторы hdac6, способ их получения и их применение | |
| CN121405694A (zh) | Oga抑制剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ METHODS OF MAKING TRANS ISOMERIC FORMS OF G PROTEIN-COUPLED RECEPTOR MODULATORS |
|
| SREP | Specification republished |